Jul 14, 2024 · Antiplatelet medicines work to make your platelets less sticky and thereby help prevent blood clots from forming in your arteries. Aspirin is an antiplatelet medicine that may be used. P2Y12 receptor blockers are another group of antiplatelet medicines.

Patients treated with elinogrel, a reversible and competitive P2Y12-receptor antagonist which requires no metabolic activation, had greater inhibition of platelet aggregation than those treated with clopidogrel.

Oct 30, 2017 · Dual antiplatelet therapy with aspirin and a platelet P2Y 12 receptor antagonist (P2Y 12 inhibitor) is the treatment of choice for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS) and for those undergoing percutaneous coronary intervention (PCI). 1, 2 Clopidogrel, prasugrel, and ticagrelor are the most ...

Three oral P2Y 12 inhibitors are available: clopidogrel, prasugrel, and ticagrelor (Brilinta, AstraZeneca). Clopidogrel, the first P2Y 12 inhibitor, was the standard for DAPT until newer options became available.

Current treatment guidelines (AHA and ESC) recommend the use of dual oral antiplatelet therapy consisting of aspirin and a platelet P2Y12 receptor antagonist for the management of patients with ACS and/or patients undergoing PCI in order to prevent stent thrombosis and future atherothrombotic events.

Newer P2Y12 receptor antagonists are associated with better cardiovascular outcomes in patients with ACS and/or undergoing PCI. Prasugrel use resulted in higher major bleeding rates and no overall mortality benefit compared with clopidogrel.

Jan 3, 2008 · Novel P2Y 12 antagonists, including prasugrel, AZD6140, and cangrelor, have a faster onset of action, as well as more potent, and less variable, inhibition of platelet function ex vivo.

P2Y 12 receptor antagonists are now the primary mode of treatment for acute coronary syndromes and for patients undergoing percutaneous coronary intervention with stenting. Antagonism of the receptor inhibits ADP-mediated platelet aggregation and results in a reduction in occlusive thrombotic events. Four FDA-approved agents are currently in use.

Jan 5, 2022 · Several Molecular modelling studies that lead to the discovery of novel P2Y 12 antagonists. P2Y 12 is a platelet surface protein which is responsible for the amplification of P2Y1 response. It plays a crucial role in platelet aggregation and thrombus formation through an ADP-induced platelet activation mechanism.

P2Y12 inhibitors are antiplatelet medications that work by blocking the P2Y12 receptor on platelet surfaces. P2Y12 inhibitors are used to stop thrombotic events in a range of cardiovascular conditions by reducing the chance of clot formation.